National_Coverage_Determinations_Manual / NaF-18 PET to Identify Bone Metastasis of Cancer 220.6.19

Why This Topic Matters

Coverage for advanced PET imaging can depend on the clinical setting, study participation, and CMS policy language. Understanding the scope of this NCD helps organizations assess medical necessity, reimbursement risk, and compliance requirements for oncology-related imaging services.

Article Sections

1. A. General

   Introduces PET imaging and the clinical context for evaluating suspected bone metastases in cancer. Provides broad background on the imaging modality and its relevance to oncology care.

2. B. Nationally Covered Indications

   Describes the circumstances under which CMS covers NaF-18 PET within prospective clinical study settings. Summarizes the research and participation standards referenced by the policy.

3. C. Nationally Non-Covered Indications

   States the non-covered scope for NaF-18 PET uses outside the specified covered circumstances. Explains the general coverage limitation referenced by the determination.

4. D. Other

   Notes the PET radiopharmaceutical agents identified in the policy context. Provides a brief closing reference to the coverage framework for PET cancer imaging.